Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Balanced Salt Solution Clear all
Completed Phase 3 Interventional

Safety of OMS103HP in Patients Undergoing Anterior Cruciate Ligament (ACL) Reconstruction

NCT00245271
View directory record Official record
Conditions
Anterior Cruciate Ligament Reconstruction
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
17 Years to 65 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
10
States / cities
Los Angeles, California • Redwood City, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 5, 2026, 7:16 PM EDT
Terminated Phase 4 Interventional

Hyaluronic Acid Gels for Upper Lid Retraction in Active Stage Thyroid Eye Disease

NCT01738243
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Hyaluronic Acid Gel injection, Saline injection
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK1322322 in Healthy Subjects

NCT01648179
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 (mesylate salt) Powder for Injection, GSK1322322 (freebase) tablets, GSK1322322 (mesylate salt) Powder for Oral Solution, GSK1322322 (freebase) tablets FED
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

NCT02132312
View directory record Official record
Conditions
Unilateral Cataract Extraction, Congenital Cataract
Interventions
OMS302, Phenylephrine HCl
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
1 Day to 47 Months
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
11
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2021 · Synced Sep 5, 2026, 7:16 PM EDT
Recruiting Not applicable Interventional

Efficacy of SynEx Wound Rinse in Civilian Surrogates of Combat Injury Wounds

NCT05743283
View directory record Official record
Conditions
Wound Heal
Interventions
SynEx Wound Cleanser, Saline
Device · Other
Lead sponsor
Synedgen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 15, 2024 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional

Exploratory Study of OMS302 Injection in Subjects Undergoing Unilateral Cataract Extraction by Phacoemulsification.

NCT00721695
View directory record Official record
Conditions
Cataract Extraction
Interventions
OMS302, OMS302-PE, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
50 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
4
States / cities
Redding, California • Bloomington, Minnesota • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Evaluation of Balanced Salt Solution During Cataract Surgery

NCT05853978
View directory record Official record
Conditions
Fuchs Dystrophy, Cataract
Interventions
BSS Plus, BSS
Drug
Lead sponsor
Adam Fedyk, MD, FACS
Other
Eligibility
22 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
Town and Country, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

NCT01115517
View directory record Official record
Conditions
Pterygium
Interventions
Bevacizumab, Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 5, 2026, 7:16 PM EDT
Not yet recruiting Phase 3 Interventional

RB-PDT for Fusarium Keratitis: The LUMIERE Study

NCT07743489
View directory record Official record
Conditions
Fusarium Keratitis
Interventions
Rose Bengal Photodynamic Therapy, Sham RB-PDT
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2030
U.S. locations
2
States / cities
Palo Alto, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 5, 2026, 7:16 PM EDT
Recruiting Phase 4 Interventional

Does Topical Ophthalmic Proparacaine 0.5% Prior to Probing and Irrigation Decrease Pain?

NCT05663684
View directory record Official record
Conditions
Epiphora, Dacryostenosis, Dacryocystitis
Interventions
Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 3, 2013 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ahmed Glaucoma Valve Surgery With Mitomycin-C

NCT02805257
View directory record Official record
Conditions
Glaucoma, Primary Open Angle Glaucoma, Secondary Glaucoma, Neovascular Glaucoma
Interventions
Mitomycin-C, Balanced Salt Solution, Ahmed Glaucoma Valve Implant
Drug · Other · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 85 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 Mutation

NCT02652767
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 7:16 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Sodium Thiosulfate Eardrops on Hearing Loss in Patients Who Receive Cisplatin Therapy

NCT01369641
View directory record Official record
Conditions
Cancer
Interventions
Insertion of Pressure Equalization (PE) Tubes, Sodium Thiosulfate (STS), Saline (Placebo), Cisplatin
Procedure · Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1 Interventional Results available

Pragmatic Pediatric Trial of Balanced Versus Normal Saline Fluid in Sepsis: A Pilot Feasibility Study

NCT03340805
View directory record Official record
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 4, 2019 · Synced Sep 5, 2026, 7:16 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Hypertonic Saline in Posterior Spinal Fusion

NCT06822374
View directory record Official record
Conditions
Scoliosis Idiopathic, Scoliosis;Congenital
Interventions
Normosol-R, buffered 2% hypertonic saline
Drug
Lead sponsor
Joseph D. Tobias
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)

NCT02652780
View directory record Official record
Conditions
Optic, Atrophy, Hereditary, Leber
Interventions
GS010, Sham Intravitreal Injection
Biological · Device
Lead sponsor
GenSight Biologics
Industry
Eligibility
15 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Isotonic Solutions and Major Adverse Renal Events Trial in the Non-Medical Intensive Care Unit (SMART-SURG)

NCT02547779
View directory record Official record
Conditions
Critical Illness, Acute Kidney Injury
Interventions
0.9% Saline, Physiologically-balanced isotonic crystalloid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
10,421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Not applicable Interventional Results available

Isotonic Solution Administration Logistical Testing

NCT02345486
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
0.9% sodium chloride, Physiologically balanced fluid
Other
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 1 Interventional

Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions

NCT00660166
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia
Interventions
NK-Cell Infusion
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
13 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 26, 2012 · Synced Sep 5, 2026, 7:16 PM EDT
Completed Phase 4 Interventional Results available

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

NCT00798577
View directory record Official record
Conditions
Bacterial Conjunctivitis
Interventions
Vigamox Ophthalmic Solution, BSS placebo
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
1 Year and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Sep 5, 2026, 7:16 PM EDT